Clinical trial
Weekly Carboplatin/Docetaxel for Recurrent Ovarian/Peritoneal Cancer
NCT00214058 · University of Wisconsin, Madison, Other · Completed
Key facts
| NCT number | NCT00214058 |
|---|---|
| Title | Weekly Carboplatin/Docetaxel for Recurrent Ovarian/Peritoneal Cancer |
| Official title | Phase II Evaluation of Weekly Docetaxel in Combination With Weekly Carboplatin in the Treatment of Recurrent Epithelial Ovarian Carcinoma |
| Lead sponsor | University of Wisconsin, Madison, Other |
| Collaborators | Aventis Pharmaceuticals Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Ovarian Carcinoma, Primary Peritoneal Carcinoma |
| Intervention type | Drug |
| Interventions | Carboplatin, Docetaxel |
| Enrollment | 36 |
| Start date | Aug 1, 2002 |
| Completion | Feb 1, 2006 |
| First posted | Sep 21, 2005 |
| Last update posted | Nov 19, 2019 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: